Plain-English translation of NCT03847467 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a dietary supplement called (2'-FL) to see if it is safe and well-tolerated in young people with inflammatory bowel disease (IBD) — specifically Crohn's disease or ulcerative colitis — who are already receiving stable biologic therapy. The researchers believe this medication may help increase beneficial bacteria in the gut and improve the body's natural defense system. The study will test three different daily doses of the supplement, plus a placebo group, to find the best and safest dose.
Inflammatory bowel disease causes ongoing inflammation in the digestive system, and researchers believe that the balance of bacteria in the gut plays an important role in managing the condition. This trial exists to see whether the medication can safely help restore that balance in young people already doing well on their current treatment, potentially offering an additional tool to keep their disease in remission.
You likely qualify if…
You likely don't qualify if…
You would take a daily dose of either the dietary supplement or a placebo (inactive substance) for several weeks as part of this two-phase study. The first phase focuses on safety in young adults aged 18–25, and if that goes well, the second phase expands to include younger participants (ages 11–17). Throughout the study, you'll have clinic visits where the research team will check on how you're doing, collect stool samples to measure bacteria in your gut, and monitor your overall health. The study is designed to last several months, and you'll need to keep taking your regular biologic medication exactly as prescribed.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States